|
|
|
|
| LEADER |
05757nam a2200637 4500 |
| 001 |
ocn919430985 |
| 003 |
OCoLC |
| 005 |
20180501122027.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
150831s2015 mau o 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d OPELS
|d N$T
|d OPELS
|d YDXCP
|d IDEBK
|d CDX
|d OCLCF
|d EBLCP
|d VT2
|d OCLCQ
|d GrThAP
|
| 019 |
|
|
|a 919564816
|a 919875264
|a 923547144
|
| 020 |
|
|
|a 9780128016213
|q electronic bk.
|
| 020 |
|
|
|a 0128016213
|q electronic bk.
|
| 020 |
|
|
|a 9780128014806
|
| 020 |
|
|
|a 0128014806
|
| 035 |
|
|
|a (OCoLC)919430985
|z (OCoLC)919564816
|z (OCoLC)919875264
|z (OCoLC)923547144
|
| 050 |
|
4 |
|a RC365
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.8/3
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Omic studies of neurodegenerative disease.
|n Part A /
|c edited by Michael J. Hurley.
|
| 264 |
|
1 |
|a Waltham, MA :
|b Academic Press is an imprint of Elsevier,
|c 2015.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a International review of neurobiology ;
|v volume 121
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Title details screen (ScienceDirect, viewed September 3, 2015).
|
| 520 |
|
|
|a Omic Studies of Neurodegenerative Disease: Part B is part of a well-established international series on neuroscience that examines major areas of basic and clinical research, along with emerging and promising subfields. The book informs the reader on the current state of the studies used to evaluate the mechanisms, causes, and treatment of neurodegeneration through a combination of literature reviews and examples of current research.
|
| 504 |
|
|
|a ""References""""Chapter Three: Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases""; ""1. Introduction""; ""2. Proteomic Methods Utilized in Understanding Neurodegenerative Diseases""; ""2.1. Two-Dimensional Gel Electrophoresis""; ""2.2. Mass Spectrometry""; ""3. AlzheimerÂ?s Disease""; ""3.1. Pathophysiology""; ""4. AD Biomarkers""; ""4.1. Brain Tissue""; ""4.2. Cerebrospinal Fluid""; ""4.3. Plasma""; ""5. ParkinsonÂ?s Disease""; ""5.1. Pathophysiology of ParkinsonÂ?s Disease""; ""6. PD Biomarkers""; ""6.1. Ccerebrospinal Fluid""; ""6.2. Plasma""; ""6.3. Brain Tissue""
|
| 505 |
0 |
|
|a ""Front Cover""; ""Omic Studies of Neurodegenerative Disease: Part A""; ""Copyright""; ""Contents""; ""Contributors""; ""Preface""; ""Chapter One: AlzheimerÂ?s Disease: Genomics and Beyond""; ""1. Introduction""; ""2. GWASs on the Primary Phenotype of AD""; ""3. GWASs on the Secondary Phenotype of AD""; ""4. CNV Studies""; ""5. WES and WGS Studies""; ""6. Functional Genomics Studies""; ""7. Brain Transcriptome Studies""; ""8. Early-Onset AD""; ""9. Epigenomics Studies in the Brain""; ""10. AD, Brain Aging, and Longevity""; ""11. AD and Relevant Diseases""
|
| 505 |
8 |
|
|a ""12. Seeking Peripheral Biomarkers""""13. Animal Studies of AD""; ""14. iPSC Technology in AD Research""; ""15. Integrating Multiomics Information for AD""; ""16. Concluding Remarks""; ""Acknowledgments""; ""References""; ""Chapter Two: The Potential of Proteomics in Understanding Neurodegeneration""; ""1. Introduction""; ""2. Cellular Mechanisms of Neurodegeneration""; ""3. Fundamentals of Proteomics""; ""3.1. Common Proteomic Protocols""; ""3.2. Specifics of Proteomic Protocols""; ""4. Application of Proteomics in Neurodegenerative Diseases""
|
| 505 |
8 |
|
|a ""4.1. Proteomic Approaches Using Animal Models""""4.2. Proteomic Approaches Using Human Cells and Tissue""; ""4.3. Proteomic Characterization of Biological Fluids for Biomarker Discovery""; ""4.3.1. ParkinsonÂ?s Disease""; ""4.3.2. AlzheimerÂ?s Disease""; ""4.3.3. HuntingtonÂ?s Disease""; ""4.3.4. Amyotrophic Lateral Sclerosis""; ""4.3.5. Other Neurodegenerative Diseases""; ""5. From Proteomics to Clinical Significance: Targeting Signaling Pathways in Neurodegenerative Diseases""; ""6. Future Perspectives: Combinatorial Genomic, Metabolomics, and Proteomic Analysis""; ""Acknowledgments""
|
| 505 |
8 |
|
|a ""7. HuntingtonÂ?s Disease""""7.1. Pathophysiology""; ""7.2. Mitochondrial Dysfunction in HD""; ""7.3. Oxidatively Modified Proteins in HD""; ""7.4. PTM Specific to htt Protein""; ""8. Prion Diseases""; ""8.1. Pathophysiology""; ""9. Prion Biomarkers""; ""9.1. Brain""; ""9.2. Cerebrospinal Fluid""; ""10. Amyotrophic Lateral Sclerosis""; ""10.1. Pathophysiology""; ""11. ALS Biomarkers""; ""11.1. Cerebrospinal Fluid""; ""11.2. Plasma""; ""11.3. Other Biofluids""; ""12. Conclusion""; ""References""; ""Chapter Four: Uncovering Neurodegenerative Protein Modifications via Proteomic Profiling""
|
| 650 |
|
0 |
|a Nervous system
|x Degeneration.
|
| 650 |
|
0 |
|a Molecular neurobiology.
|
| 650 |
|
7 |
|a HEALTH & FITNESS / Diseases / General
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Clinical Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Diseases
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Evidence-Based Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Internal Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a Molecular neurobiology.
|2 fast
|0 (OCoLC)fst01024815
|
| 650 |
|
7 |
|a Nervous system
|x Degeneration.
|2 fast
|0 (OCoLC)fst01036090
|
| 655 |
|
4 |
|a Electronic books.
|
| 655 |
|
0 |
|a Electronic books.
|
| 700 |
1 |
|
|a Hurley, Michael J.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Hurley, Michael J.
|t Omic Studies of Neurodegenerative Disease - Part A
|d : Elsevier Science,c2015
|z 9780128014806
|
| 830 |
|
0 |
|a International review of neurobiology ;
|v volume 121.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/00747742/121
|z Full Text via HEAL-Link
|
